Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Research Regulatory News (EDEN)

Share Price Information for Eden Research (EDEN)

Share Price is delayed by 15 minutes
Get Live Data
3.30    0.00 (0.00%)
Bid:
3.20
Ask:
3.40
Spread: 0.20 (6.25%)
Market Cap: £26.51m
EDEN Live PriceLast checked at - London Stock Exchange

Intraday Eden Research Share Chart

Data Access Licence and Royalty Agreement

13 Jan 2014 07:00

RNS Number : 4441X
Eden Research plc
13 January 2014
 



 

Eden Research Plc

("Eden" or "Company")

 

Data Access Licence and Royalty Agreement

 

Eden Research plc (AIM: EDEN), the AIM listed natural micro-encapsulation company, announces that it has granted access to its EU regulatory data and dossiers to Desarrollo Agricola y Minero S.A. ("Daymsa") of Zaragoza, Spain.

 

In 2013, Eden received approval for three active substances under the European Union Regulation ("EC") No. 1107/2009 concerning the Placing of Plant Protection Products on the Market. This data, which was generated by Eden to register its own plant protection product 3AEY, is also of value to third parties as a basis to register their own products using one or more of the same active substances.

 

Daymsa already uses similar natural ingredients in its existing product portfolio and shall now register new products using the data for the active substances registered by Eden.

 

Clive Newitt, Managing Director of Eden comments: "Having invested a considerable amount of time, money and effort into the EU approvals of the three active substances, it is pleasing to see a return on our investment through upfront and milestone payments, as well as royalties on commercial sales. Daymsa is a well-established business with presence in Europe and Latin America and so the potential reach of these new products is significant."

 

Juan Pardos, General Manager of Daymsa comments: "Daymsa, a leading producer in Europe of Leonardite, is a 34 year old Spanish company that specialized in "Bio-stimulant and Bio-control products" even before those terms became of general use in ecological and conventional agriculture. This strategic agreement with Eden will enable us to become a leading company in Europe not only as leading producer of Leonardite but also a leading producer of "Vegetable Extract based" Bio-Control products."

 

Enquiries:

 

Eden Research plc

www.edenresearch.com

Clive Newitt, Managing Director

Tel: 01993 862 761

Alex Abrey, Chief Financial Officer

W H Ireland Limited

Tel: 0117 945 3471

John Wakefield

Walbrook PR Ltd

Tel: 020 7933 8780 or eden@walbrookpr.com

Paul McManus (Media Relations)

Mob: 07980 541 893

Paul Cornelius (Investor Relations)

Mob: 07827 879 496

 

 

 

 

Notes:

 

Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.

 

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with hydrophobic compounds both natural and synthetic. The technology uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

 

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

 

With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

 

The Company has a number of patents and has a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, identifying suitable industrial partners and entering into licence agreements.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

 

For more information about Eden, please visit www.edenresearch.com

  

 

 

 

 

Daymsa, Europe´s leading producer of Leonardite started producing Leonardite based soil amendment products as early as in 1979. Since that time our investment in Quality and Sustainable Agriculture has been strengthened with the development of a full range of Bio-stimulant and Bio-control Products.

 

The increase in the world's population, a higher percentage of the world population entering the consumer market and the harsh competition of the Bio-Fuels over the limited land resources compelled Bio-technological companies like Daymsa to force their Research and Development departments into the search for solutions that can help to increase the world production of food, maintaining and increasing the long term quality and richness of the land.

 

The Sustainable Agriculture Solutions of Daymsa include a full range of

a) Soil and water conditioners

b) Bio-stimulants

c) Bio-control Products

d) Specialized microelement deficiency amendments

 

The actual Biocontrol portfolio products of Daymsa is based on the broad experience of Daymsa and its three subsidiary companies established in Brazil, Colombia and Ecuador not only in the European and Southern American market but also in the Middle East and North American countries. The Strategical Agreement signed with Eden will allow Daymsa to become one of the first producer of very effective Plant Protection Products based on Plant Extracts Registered in Europe.

 

For more information about Daymsa, please visit www.daymsa.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRGGUPCGUPCGQP
Date   Source Headline
27th May 20267:00 amRNSDirectorate change
28th Apr 20267:00 amRNSTrading Update
16th Apr 20262:59 pmRNSHolding(s) in Company
14th Apr 20264:30 pmRNSHolding(s) in Company
14th Apr 20263:31 pmRNSHolding(s) in Company
13th Apr 202611:31 amRNSHolding(s) in Company
10th Apr 20267:00 amRNSCompletion of Conditional Placing and TVR
8th Apr 202612:10 pmRNSSatisfaction of Conditions of Conditional Placing
2nd Apr 20267:00 amRNSThymolflex EPA approval
19th Feb 20263:59 pmRNSHolding(s) in Company
19th Feb 20261:29 pmRNSHolding(s) in Company
18th Feb 20269:40 amRNSResult of General Meeting and Total Voting Rights
5th Feb 20262:50 pmRNSResult of Retail Offer
2nd Feb 20261:01 pmRNSLaunch of Retail Offer
2nd Feb 202612:57 pmRNSProposed Placing and Subscription
9th Jan 20267:00 amRNSNovellus+ Regulatory Authorisation in Chile
7th Jan 20267:00 amRNSMevalone Label Extension in France
18th Dec 20257:00 amRNSAppointment of Syngenta as Distribution Partner
20th Nov 20257:00 amRNS3LOGY Label Extension in Italy
17th Nov 20257:00 amRNSEcovelex 2025 Approval in Italy
17th Sep 20259:45 amRNSDirector/PDMR Shareholdings
17th Sep 20258:36 amRNSDirector/PDMR Shareholdings
17th Sep 20257:00 amRNSHalf Yearly Report
15th Sep 20257:00 amRNSNotice of Results
18th Jun 20251:40 pmRNSResult of AGM
18th Jun 20257:00 amRNSAGM Statement
16th Jun 20257:00 amRNSEcovelex Partnership with Royal Holloway
27th May 20255:22 pmRNSNotice of AGM
13th May 20257:00 amRNSMevalone Approval in California - Powdery Mildew
9th May 20257:00 amRNS-RInvestor Presentation via Investor Meet Company
6th May 202512:08 pmRNSHolding(s) in Company
6th May 20257:00 amRNSPreliminary results for the year ended 31 Dec 2024
10th Apr 20257:00 amRNSThymol Supply Agreement For Bee Health
1st Apr 202510:08 amRNSDirector/PDMR Shareholdings
24th Mar 20257:00 amRNSAppointment of Distribution Partner in Kenya
10th Mar 20257:00 amRNSAppointment of Joint Broker
5th Mar 202512:52 pmRNSDirector/PDMR Shareholding
5th Mar 20257:00 amRNSDirector/PDMR Shareholding
4th Mar 20252:13 pmRNSDirector/PDMR Shareholdings
6th Feb 20252:08 pmRNSDirector/PDMR Shareholding
5th Feb 20257:00 amRNS-RInvestor Presentation via Investor Meet Company
28th Jan 202510:36 amRNSDirector/PDMR Shareholdings
13th Jan 20257:12 amRNSTrading Update
20th Dec 20247:00 amRNSRegulatory approval for Novellus+ in Mexico
16th Dec 20247:00 amRNSAppointment of Distributor in Austria
11th Dec 20247:00 amRNSMevalone Organic Input Registration in Germany
7th Nov 20247:01 amRNSTrading Update
7th Nov 20247:00 amRNSEcovelex Approval in Italy
8th Oct 202411:24 amRNSOTCQB exchange update
23rd Sep 20247:00 amRNSHalf yearly Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.